Foghorn Therapeutics opened lower at $2.07, compared with its previous close of $2.09. In the last trading session, the stock traded between $1.95 and $2.08. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Foghorn Therapeutics is now worth
$ 14.85
Resulting in a loss of
$ 85.15 (85.15%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
28.57%
Hold
71.43%
Sell
0%
Markets Today
Today's Change
$-0.04 (-1.67%)
Day High
$2.08
Day Low
$1.95
Day Open
$2.07
Prev Close
$2.09
Volume
5,17,633
1W Return
-2.38%
1M Return
5.12%
3M Return
-68.83%
6M Return
-52.54%
1Y Return
-53.72%
Fundamentals
Market Cap ($ Mn)
123
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-51.18%
EPS (TTM)
$0.97
Investment Returns
1 Week
-2.38%
1 Month
5.12%
3 Months
-68.83%
6 Months
-52.54%
9 Months
-62.08%
Financials
Quarterly
All values in $ Mn
6.0
Mar 25
7.6
Jun 25
8.2
Sep 25
9.2
Dec 25
16.1
Jun 26
83.5
Sep 26
Updates
9Nov
Foghorn Therapeutics posts $58.2M net income on catch-up adjustment
Net income reached $58.2 million in Q3 2026, reversing a $15.8 million loss in Q3 2025. Collaboration revenue jumped to $83.5 million, driven by a $74.1 million cumulative catch-up adjustment. Cash, cash equivalents, and marketable securities totaled $156.2 million as of September 30, 2026. IND filing for Selective EP300 degrader targeted for 2027; first-in-human trials for IBD program expected by end of 2027.
3 days ago
4Nov
Pomerantz investigates Foghorn Therapeutics after 30% stock drop
Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. The probe follows a 30.82% drop in stock price to $2.02 per share on October 2, 2026. Foghorn halted the FHD-909 clinical trial and the Selective SMARCA2 degrader program. The company announced a workforce reduction of approximately 40% to preserve cash.
9 days ago
12Oct
Foghorn faces second legal probe as SBS Law joins Lilly halt case
Schall, Brown & Schwartz LLP joins Pomerantz LLP in investigating Foghorn Therapeutics for securities fraud. Stock fell 30.82% to $2.02 after Foghorn halted Eli Lilly collaboration on FHD-909. Company cut 40% of workforce to extend cash runway into second half of 2029. Cash balance stood at $167.6 million as of June 30, 2026.
1mo ago
2Oct
BTIG downgrades Foghorn Therapeutics to Neutral from Buy
BTIG analyst Jeet Mukherjee downgraded Foghorn Therapeutics to Neutral. The previous rating for the stock was Buy. No specific financial figures or target prices were disclosed.
Foghorn Therapeutics exceeded Q2 expectations with sales of $16.072 million, up 112.68% YoY, and EPS of $(0.10), beating estimates by 54.55%. The results highlight strong top-line growth and narrowing losses compared to the prior year.
